Seeing the Big Picture Highlights from 2019
Leadership Director Michelle Le Beau, PhD Deputy Director Walter Stadler, MD Associate Director for Population Research Habibul Ahsan, MBBS, MMedSc Associate Director for Education M. Eileen Dolan, PhD Associate Director for Basic Sciences Geoffrey Greene, PhD Associate Director for Community Outreach and Engagement Karen Kim, MD Associate Director for Clinical Sciences
At the end of a year and—in this case— a decade, it helps to see the big picture. Cancer survivors in the U.S. number almost 17 million, and overall cancer death rates are falling. These trends reflect significant progress made over the past few decades in cancer prevention, early diagnosis and treatment. The year-end highlights included herein illustrate the many ways our physicians and scientists contribute to the larger picture of progress in cancer research. Thanks for your support!
Mark Ratain, MD Associate Director for Administration Marcy List, PhD/ Kathleen Goss, PhD
Michelle M. Le Beau, PhD Director, The University of Chicago Medicine Comprehensive Cancer Center; Arthur and Marian Edelstein Professor of Medicine
Research
The collective group of diseases known as cancer is one of the most important crises of our time. It takes a dedicated team of scientists from a variety of backgrounds to unravel cancer’s many complexities.
The Types of Cancer Research Driving Progress
Basic research
3 2 1 4
Seeks to answer fundamental biological questions about the molecular and cellular events that collectively result in cancer
Translational research
Clinical research
Bridges laboratory discoveries and their application to cancer patients, including the development of innovative new treatments
Studies cancer in people, often through clinical trials testing newly developed prevention, diagnosis or treatment approaches
Population research
Gains new insights into disease and health at a population level, such as how to prevent cancer and identify those at risk, as well as help survivors overcome challenges
Highlights from 2019
1
Research Highlights
These high-impact discoveries of 2019 helped to move the cancer research field forward.
Pancreatic cancer cells imaged in the laboratory of Kay Macleod, PhD.
Basic research
New answers to a long-standing mystery behind cell metabolism Understanding how different types of cells fuel themselves, or metabolize nutrients, is an attractive area of study because new drugs could be developed to interrupt and exploit the process. Metabolism also plays a role in the responsiveness of immune cells that protect against harmful pathogens, such as viruses, bacteria and the body’s own cells that have changed, such as cancerous cells. For the first time, Yingming Zhao, PhD, Lev Becker, PhD, and colleagues made a key discovery about how cellular metabolism affects the cell’s function. Their study shows that lactate, an end product of metabolism, changes the function of an immune cell known as a macrophage, thereby rewiring it to behave differently. This discovery serves as a blueprint to understand how lactate alters other cell types, such as T cells and cancer cells. More research is needed, but the discovery draws an exciting link between cellular metabolism and gene regulation that was previously unknown. ZHANG ET AL., NATURE 574:575-80, 2019.
2
Seeing the Bigger Picture
Clinical research
Clinical research
Finding breast cancer earlier in women with genetic mutations
Blood test identifies risk of lymphoma’s return
For younger women at high risk of developing breast cancer because of genetic mutations, such as in the BRCA1 or BRCA2 genes, an annual mammogram can miss fast-growing tumors that are likely to spread. Olufunmilayo Olopade, MD, and several UChicago Medicine Comprehensive Cancer Center colleagues found that having an MRI twice a year is better at catching aggressive breast cancers earlier. The earlier a breast cancer is diagnosed, the better the survival outcome. For most women, an annual mammogram is still important, but for this group of high-risk women, getting MRIs twice yearly can take the place of annual mammograms as a screening strategy. The research team is conducting further studies evaluating this novel screening approach to personalize breast cancer risk assessment and prevention, including new MRI techniques developed at our institution that can make the scans faster and less expensive.
Around 20% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will experience a relapse after their first round of treatment. Current procedures for monitoring treatment response by imaging have not improved survival, and other approaches involve invasive biopsies. Brian Chiu, PhD, and Chuan He, PhD, developed a sensitive blood test for predicting clinical outcomes of lymphoma. The test analyzes circulating cell-free DNA, genetic fragments released by tumor cells into the blood. Certain epigenetic markers are associated with higher risk of relapse or death from DLBCL after receiving treatment. The simple blood test, taken at the time of diagnosis, could help predict which patients may need more intensive treatment. If the findings are validated in a large group of patients, this approach could impact the cure rate for DLBCL.
GUINDALINI ET AL., CLIN CANCER RES. 25:1786-94, 2019.
CHIU ET AL., BLOOD ADV 3:2790-99, 2019.
Team members work in a clean room in the new Advanced Cellular Therapeutics Facility.
Highlights from 2019
3
Research Highlights
Population research
Survivors of childhood cancer face unique health problems
Translational research
Old drugs, new uses An estimated 15% to 20% of all breast cancer patients have aggressive triple-negative breast cancer that is currently treated with standard chemotherapy. This treatment-resistant cancer disproportionately affects younger women, women of African descent and women with mutations in the BRCA1 gene. The lack of better medicines for this group of patients prompted a team led by Marsha Rosner, PhD, to look for novel drug targets and new ways to disrupt disease-causing pathways. They demonstrated that two older drugs that are already in the marketplace, metformin and hemin, can be combined to target two cellular processes that are key to tumor growth and spread—a protein called BACH1 and mitochondrial metabolism. When tested in animal models, the new combination therapy produced encouraging results and may have applications in other types of cancer beyond breast cancer. LEE ET AL., NATURE 568; 254-58, 2019.
4
Seeing the Bigger Picture
Childhood cancer survivors need specialized care as they age to minimize health problems and identify diseases early. The very same treatments that cured their disease can leave them at risk for a host of later-in-life complications, including cardiac disease and second cancers. Using a large database compiled across North America, Tara Henderson, MD, MPH, and colleagues showed that female childhood cancer survivors died after a breast cancer diagnosis more frequently than women who had previously been cancer-free. In fact, they were five times more likely to die as a result of other diseases, including secondary cancers and heart and lung diseases. The rate of ensuing deaths reflects the burden of facing multiple diseases and highlights the need for risk-reducing interventions and ongoing surveillance to ensure any new problems are caught early. In addition, our researchers are now developing a breast cancer risk prediction model for survivors. MOSKOWITZ ET AL., J CLIN ONCOL 37:212030, 2019.
Population research
‘No Smoker Left Behind’ helps cancer patients quit smoking Quitting smoking is the most important lifestyle change patients can make to decrease their risk of developing cancer. The National Cancer Institute (NCI) and its Cancer Moonshot initiative have dedicated resources to help selected cancer centers develop comprehensive smoking cessation programs. The goal is to fund programs that serve as an example of how cancer patients who use tobacco should be treated. Of the 71 NCI-designated cancer centers, only 22—including our cancer center—were selected to lead this initiative in its first year. Our program, No Smoker Left Behind, is specifically designed to help cancer patients stop smoking through evidence-based treatment options. For six months, a team led by Andrea King, PhD, and Yasmin Asvat, PhD, track participants’ progress and connect them to services as needed, such as on-site individual or group counseling, telephone-based support and nicotine replacement therapy.
Basic research
What happens when red blood cell production goes haywire? Focusing on how the production of red blood cells is triggered, our researchers identified a key protein that could serve as a drug target to cure a group of blood diseases. Blood cells are produced by stem cells. Upon receiving special molecular signals known as cytokines, these impressionable stem cells start to mature into various types of blood cells. Any flaws in the regulation of this process can have dire consequences, such as cancer or anemia. Pre-cancerous blood diseases associated with the overproduction of blood cells are often treated by targeting the mutated Janus kinase 2 (JAK2) protein, which is essential for cell growth and division. JAK2 resides in the cell and is activated when exterior cytokines bind to the cell surface. Until recently, the link between JAK2, cytokines and the genes that control blood cell production remained an enigma. Amittha Wickrema, PhD, and colleagues were the first to complete this connection by identifying a crucial second protein in this communication pathway, the tet methylcytosine dioxygenase 2 (TET2).
TET2 directly communicates with the DNA encoding genes in the nucleus, and it can be indirectly activated by cytokines through the JAK2 protein. This research suggests that drugs tailored toward TET2 activation may be more effective than those drugs that only target JAK2. If proven successful, this could be an important step toward optimizing treatments for blood disorders. JEONG ET AL., CANCER DISCOV 9:778-95, 2019.
Clinical research
Refining treatment strategy for childhood cancer based on new data Neuroblastoma is one of the most common cancers in childhood. Being able to predict the aggressiveness of a tumor informs the most appropriate course of treatment. A research team led by Susan Cohn, MD, and Mark Applebaum, MD, has discovered a new way to identify potentially high-risk pediatric neuroblastoma tumors. They analyzed the DNA profiles of tumors and identified 577 genes with a DNA modification called 5-hydroxymethylcytosine (5-hmC), which helps to switch genes on
and off. In recent years, 5-hmC has been found to be a strong biomarker, or indicator, for how adult cancers will act. Using this information, the researchers were able to categorize the patients into those who would have a “favorable” or “unfavorable” response to therapy. In 2019, Cohn and colleagues also made progress in intermediaterisk neuroblastoma. Results from a large, collaborative clinical trial showed that specific subsets of neuroblastoma patients can be treated less aggressively and still achieve excellent survival. For the study, the researchers assigned eligible patients to receive two, four or eight cycles of chemotherapy based on various factors like age at diagnosis, stage, genetic features of the tumor and more. Over 95% of the patients studied survived for three years. The refined treatment strategies will serve as the new standard of care for intermediate-risk patients going forward. APPLEBAUM ET AL., JCO PRECIS ONCOL 3:10, 2019; TWIST ET AL., J CLIN ONCOL 34;3243-55, 2019.
Clinical research
A game-changer for pancreatic cancer
option for pancreatic cancer. Findings from a clinical trial found that the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer for patients who carry a mutation in the BRCA1 or BRCA2 genes. Olaparib is a PARP inhibitor. It blocks poly (ADP-ribose) polymerase, an enzyme involved in many cell functions, including the repair of DNA damage. In cells with ineffective DNA repair, like those with a BRCA1/2 mutation, inhibiting this enzyme causes cancer cells to die. Hedy Kindler, MD, led the POLO (Pancreas cancer OLaparib Ongoing) trial, which compared the targeted therapy vs. placebo. Among the 154 participants, those who received olaparib went 7.4 months without disease progression; those on the placebo went 3.8 months. From six months on, over twice the patients who received olaparib had no disease progression. POLO is the first phase III randomized study to establish a biomarker-driven approach for treating metastatic pancreatic cancer. Based on this work, olaparib was FDA-approved in 2019. GOLAN ET AL., N ENGL J MED 381:317-27, 2019.
One of the most exciting developments of 2019 was a new treatment Highlights from 2019
5
Our Team Our physicians and scientists are international leaders who are shaping and defining fields. Their work often results in shifting medical standards that improve patients’ quality of life.
New Members
Awards & Honors
In 2019, we welcomed 20 new members to help strengthen our efforts in key research areas.
We are proud that many of our members have been recognized on the international stage in 2019.
Advanced Imaging Research Program Tatjana Antic, MD
• Ernst Lengyel, MD, PhD, was elected to membership in the National Academy of Medicine
Molecular Mechanisms of Cancer Research Program Anindita Basu, PhD Jennifer Bennett, MD Mengjie Chen, PhD Shannon Elf, PhD Evgeny Izumchenko, PhD Alex Muir, PhD Scott Oakes, MD David Pincus, PhD Sean Pitroda, MD
• Tatyana Golovkina, PhD, was elected as a fellow of the American Association for the Advancement of Science
Cancer Prevention and Control Research Program Yasmin Asvat, PhD Clinical and Experimental Therapeutics Research Program Nicole Cipriani, MD Jagoda Jasielec, MD Xavier Keutgen, MD Katherine Kurnit, MD Andy Liao, MD John Moroney, MD Immunology and Cancer Research Program Daria Esterhazy, PhD Andrew Koh, PhD Eric Pamer, MD
6
Seeing the Bigger Picture
• Thomas Gajewski, MD, PhD, was awarded the 2019 ESMO Immuno-Oncology Award by the European Society for Medical Oncology • Richard A. Larson, MD, received the Henry M. Stratton Medal in Clinical Research from the American Society of Hematology • Susan Cohn, MD, received the American Association for Cancer Research AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
• Everett Vokes, MD, was elected president of the American Society of Clinical Oncology and Tara Henderson, MD, MPH, was elected to the board of directors • Chuan He, PhD, won the 2019 American Chemical Society Chemical Biology Lectureship Award • S. Diane Yamada, MD, became president-elect of the Society of Gynecologic Oncology • Michelle M. Le Beau, PhD, was appointed to the American Cancer Society Board of Directors and was appointed to serve on the National Cancer Institute Board of Scientific Advisors • Ralph Weichselbaum, MD, won the Gold Award from the American Society for Therapeutic Radiation Oncology • Artificial intelligence software developed by Maryellen Giger, PhD, to help radiologists more accurately diagnose breast cancer, made TIME magazine’s list of Best Inventions for 2019
Richard A. Larson, MD, accepts the Henry M. Stratton Medal in Clinical Research at the 2019 American Society of Hematology Annual Meeting.
Highlights from 2019
7
Patient Care In 2019, we applied the latest advances in cancer treatment and technology to improve patient care. Our cancer specialists work together to provide compassionate care that treats the whole person, not just their disease.
Olatoyosi Odenike, MD, specializes in all types of treatment for leukemia, including blood and bone marrow stem cell transplant.
8
Seeing the Bigger Picture
Nicole Leon with her husband and son.
New hope for Nicole When a tumor the size of a football was discovered on 32-year-old Nicole Leon’s liver, she was told there was nothing that could be done and that she would have six months to live. But a team of specialists at UChicago Medicine’s Liver Tumor Program, including Anjana Pillai, MD, and Talia Baker, MD, knew that if the tumor responded to treatment with radiation therapy, then surgical removal of the tumor would be possible. The surgery was a success. Three years later, Leon is cancer-free, married and recently gave birth to a son.
Seeking the best outcomes for patients at risk for prostate cancer Prostate cancer is one of the most common and deadly cancers for American men. There have been tremendous strides to improve the landscape of prostate cancer screening, risk assessment and management strategies. Our world-renowned prostate cancer experts, including Scott Eggener, MD, are studying hereditary factors that increase the risk for prostate cancer. They are also conducting clinical trials to test the latest prostate cancer treatments. In 2019, with funds from an anonymous donor, we opened a new High-Risk and Advanced Prostate Cancer Clinic to offer specialized care. There, men at high risk for prostate cancer can get genetic testing and a customized screening plan. Patients with recently diagnosed aggressive cancers can see our physicians for new treatment options available through clinical trials.
Rare cancer requires expert treatment
Ken Karr was at risk for prostate cancer due to his family history. He found help at the UChicago Medicine HighRisk and Advanced Prostate Cancer Clinic. Xavier Keutgen, MD, specializes in the treatment of neuroendocrine tumors.
Neuroendocrine cells can be found in almost every organ in the body. These cells release hormones when they receive messages from the nervous system. Tumors that form in these neuroendocrine cells are called neuroendocrine tumors, or NETs.
John Cunningham, MD, an expert in childhood cancers and blood diseases, sits with Remoc, the friendly green monster that greets patients, families and visitors in the lobby of Comer Children’s Hospital.
NETs are rare and complex, which is why we have a multidisciplinary and dedicated neuroendocrine tumor program consisting of nationally recognized experts who specialize in diagnosing and treating all forms of NETs. Program director Xavier Keutgen, MD, is one of the few surgeons in the country with advanced expertise in extensive removal of neuroendocrine tumors. We offer unique therapy options for even the most advanced tumors, including the new and promising PRRT, or peptide receptor radionuclide therapy. PRRT delivers radiation to NET cells without damaging other organs.
Highlights from 2019
9
Patient Care
Randy Sweis, MD, examines a patient. He is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immuno therapies.
10
Seeing the Bigger Picture
Our cancer program meets the highest standards in patient care
Medical oncologist Alexander Pearson, MD, PhD, cares for adults with head and neck cancers.
• UChicago Medicine was recertified for high-quality cancer care by ASCO, the largest oncology society in the United States. • 84 UChicago Medicine physicians made the 2019 “Top Cancer Docs” list in Chicago magazine. During the Making Strides Against Breast Cancer walk in Chicago, Kathleen Goss, PhD (left), represents UChicago Medicine on ABC7 News.
Together we answer cancer In 2019, we joined forces with the Anthony Rizzo Family Foundation, the American Cancer Society and key media outlets under the “Together We Answer Cancer” banner to raise funds for research and help patients and their families. For 11 weeks, we featured patient stories and highlighted the latest advances in cancer care, treatment and research through media partners, including the Chicago Tribune, Chicago Sun-Times, ABC7 Chicago, iHeartRadio and Hubbard Radio. Through the campaign, we encouraged the public to take action by registering in the American Cancer Society’s Chicago-area Making Strides Against Breast Cancer walks, by donating to cancer research and education or by sharing their cancer-related stories on social media.
• UChicago Medicine was nationally ranked for cancer by U.S. News & World Report for the 14th consecutive year. • UChicago Medicine’s cellular therapy program met the high standards of quality to become a FACT-accredited organization. In September 2019, the academic health system treated the 100th patient with the revolutionary cancer treatment, CAR T-cell therapy. UChicago Medicine continues to offer the most CAR T-cell therapy clinical trials in the Midwest.
Our new home online Finding cancer information from us online became a lot easier in 2019. We merged our research-focused website with the hospital’s clinical-focused website so that all content related to cancer is housed under UChicagoMedicine.org/Cancer. The new and improved site allows visitors to search easily for information about clinical trials, research, patient care, education and community outreach.
Highlights from 2019
11
Community A mobile unit brings research initiatives into the community, making it easier and more convenient for Chicago residents to participate in precision medicine clinical studies.
12
Seeing the Bigger Picture
Finding new ways to detect cancer earlier and prevent it altogether is a large part of our mission to reduce cancer’s burden on Chicago’s diverse population. We work with our community partners to bring advances in cancer research directly to the underserved neighborhoods that need them.
Serving our neighbors
In 2019, our newly reinvigorated Office of Community Engagement and Cancer Health Equity was represented at 108 community events and raised public awareness about: • Cancer prevention, early cancer detection and control; • The role of behavior, lifestyle and genetics in cancer; and • The importance of participation in cancer research and clinical trials.
Research on wheels A greater number of people on the South Side now have the opportunity to participate in research that could improve health and prevent diseases, such as cancer. Mobile units equipped with an onboard lab space were deployed into the surrounding neighborhoods to enroll community participants for various long-term public health studies, including All of Us, being conducted at the University of Chicago.
Better health begins with U Hospital employees work hard to care for patients—yet screening data suggest they do not keep up with their own routine care. The newly created HealthyU initiative ensures employees are getting the screening and education they need for cancer prevention. In 2019, we held month-long events to offer the latest information on cancer and the opportunity to sign up for colorectal, breast and cervical cancer screenings.
A community of support for Chinese-American cancer survivors A Chinese-American cancer survivor support group that formed in 2011 now has 65 active members. Chinese Strong is the first Chinese language-specific cancer support group in Illinois. Each year, the group’s activities are designed to promote positive attitudes and enhance the wellbeing of its members, including a women’s health forum, massage, chair yoga and annual field trips.
Alia Poulos, MPP, provides educational materials about cancer at a community event for seniors.
Highlights from 2019
13
Survivorship & Support More people are living longer with cancer. We support them during and after treatment and find ways to improve their quality of life. A celebration for cancer survivors In May 2019, we held our second annual cancer survivors event. We define “survivor� as anyone who has overcome cancer or is currently living with cancer. More than 150 survivors and their caregivers came to the networking and education event to hear from our experts on important topics, such as nutrition, wellness and the latest medical advances.
A cancer survivor shares her story with attendees of the celebration.
14
Seeing the Bigger Picture
A panel of experts answers audience questions about cancer survivorship.
Empowering cervical cancer survivors to become advocates Preventing cervical cancer is possible by using Pap smears, tests to detect human papillomavirus (HPV) and HPV vaccination; yet there were an estimated 13,170 new cases of cervical cancer in 2019. To address this problem, a national organization called Cervivor provides an annual training for survivors of cervical cancer to become advocates in their communities. In September 2019, 35 “cervivors� came to Chicago for Cervivor School. Nita Lee, MD, MPH, coordinated the training and recruited other faculty speakers.
Pantry gives cancer patients access to healthy foods
Survivors of stem cell transplants reunite for a celebration of life.
Food insecurity, or limited access to nutritious foods, can make recovering from cancer even more challenging. A food pantry located in the outpatient oncology space provides shelf-stable healthy food to anyone who needs it, free of charge. In 2019, 1,074 households and 3,147 individuals used the resource. That translates to a whopping 3.5 tons of groceries!
A team of physicians from UChicago Medicine draws attention to breast cancer awareness at a WNBA Chicago Sky women’s basketball game. Cervivor School trains survivors to become advocates.
Highlights from 2019
15
Survivorship & Support
Stem cell transplant survivors and their families gather for a celebration of life.
16
Seeing the Bigger Picture
Helping cancer patients navigate their care Cancer patients and their families often need extra support as they face the challenges of a cancer diagnosis. Luckily, there is help. Erika Rodriguez, a patient navi gator provided by the American Cancer Society (ACS), helps patients tap into the many financial and social resources available to them so they can focus on their treatment. In 2019, Rodriguez and the ACS provided:
Members of Geoffrey Greene’s laboratory participated in the Great Pink Run to raise awareness and funding for breast cancer research.
Going the distance for cancer awareness We participated in 12 community walks/runs for cancer in 2019. The combined distance covered was more than 40 miles, which is like walking halfway from Chicago to Milwaukee.
• 2,926 free one-way rides on public transportation (train, bus, subway) • 37 nights of lodging
Rooftop farm grows food for cancer patients
• 73 wigs • 73 referrals to cancer support groups • 103 recommendations for financial assistance • 64 connections to community resources
Crops grown on the hospital rooftop help cancer patients access healthy foods.
Using empty space on a parking structure rooftop, the UChicago Medicine nutrition services and grounds teams planted a giant vegetable and herb garden that produced a bountiful harvest. A portion of the hundreds of pounds of fresh food grown went to the hospital’s cancer patients, free of charge.
Erika Rodriguez serves as a resource for patients newly diagnosed with cancer.
Highlights from 2019
17
Education The future of cancer research lies in the hands of students of today. We offer transformative educational experiences at every career stage, including high school, undergraduate, graduate, medical school and professional.
High school students learn laboratory techniques.
Pipeline programs nurture young talent
Our training programs for high school students, undergraduates and high school science teachers continue to thrive. In 2019, Chicago EYES (Educators and Youth Enjoy Science) on Cancer and researcHStart provided immersive summer research experience, one-on-one mentorship and career development to 52 individuals, including 17 students placed at one of three of researcHStart’s partner institutions. Both programs culminated in daylong research symposia to showcase the achievements of all participants.
Finding a successful career path Summer 2019 marked the fifth year of researcHStart, a multiinstitutional program for high school students. Our alumni remain committed to careers in science. The vast majority are pursuing related undergraduate and graduate degrees at top schools nationwide, including the University of Chicago. Members of the first four researcHStart groups returned for the 2019 research symposium to inspire current trainees, who are eagerly planning their own pathways toward college and beyond. 18
Seeing the Bigger Picture
168 trainees served since 2014
45 Undergraduates
118 High schoolers
5 Science teachers
Sidney Trotter (right) was among our first high school students in summer 2014. She returned to campus in summer 2019 to continue her training for a career in research.
Highlights from 2019
19
With every initiative in 2019— whether it was providing the latest care, training future scientists or spreading knowledge in the community—we kept our focus on the bigger picture: reducing cancer’s devastating impact on the lives of our patients and their families.
Seeing the Bigger Picture Highlights from 2019
Credits Editor
Design
Jane Kollmer
Pivot Design, Inc.
Editorial advisors
Photographers
Michelle M. Le Beau, PhD Marcy List, PhD
American Society of Hematology
Kathleen Goss, PhD
Mark Black
Contributors
Chicago Corporate Photography and Video
Emily Ayshford
Jimmy Fishbein
Kat Carlton
Peter Kiar
John Easton
Robert Kozloff
Cameron Harter
Jean Lachat
Bethany Hubbard
T.W. Li
Shana Liberman
Megan Mekinda, PhD
Gretchen Rubin
National Cancer Institute
Anne Stein
Anne Ryan
Omar Villalobos
Michael Satalic
Matt Wood
Daniel Sone Joe Sternbec Nancy Wong John Zich Printing G Thomas Partners LLC
20
Seeing the Bigger Picture
Convenient locations for cancer care In 2019, as the UChicago Medicine network expands, patients have many choices for where they can go to receive world-class cancer care from our experts.
River East
290
Hyde Park 290
55
Contact Us
Naperville
Learn more UChicagoMedicine.org/Cancer
294 355
Request an appointment 1-855-702-8222
90 94
Refer a patient 1-800-824-2282
Orland Park 57
Tinley Park
Harvey
Flossmoor
Make a gift 773-702-6565
Calumet City
65
Follow us for news, events and the latest discoveries.
80
New Lenox
@UCCancerCenter
57
Schererville 55
Š 2020 The University of Chicago Medicine Comprehensive Cancer Center. All rights reserved.
5841 S. Maryland Ave., MC 1140-H212 Chicago, IL 60637-1470